Trends in Prevalence of Comorbidities in Heart Failure Clinical Trials
Muhammad Shahzeb Khan(University of Mississippi Medical Center), Javed Butler(Jackson Memorial Hospital), Alaaeddin Alrohaibani(John H. Stroger, Jr. Hospital of Cook County), Muthiah Vaduganathan(Brigham and Women's Hospital), Gregg C. Fonarow(UCLA Medical Center), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Stephen J. Greene(Duke Medical Center), Ayman Samman Tahhan(Emory University), Orly Vardeny(University of Minnesota)
Cited by 142
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k